MBX Biosciences (MBX) Q3 2026 earnings summary

Executive summary

• First patient dosed in August in the pivotal Phase 3 oPTimize trial of once-weekly canvuparatide for chronic hypoparathyroidism; MBX 5765 and MBX 6180 were nominated as obesity development candidates.

• Cash, cash equivalents and marketable securities totaled $481.6M at quarter-end, supporting the current operating plan into 2029; first-cohort MBX 4291 Phase 1 MAD results were expected in Q4 2026.

Financial highlights

• Q3 operating expenses and operating loss were $66.3M vs. $23.9M YoY; net loss was $62.4M vs. $21.6M.

• Q3 R&D expense rose to $32.0M from $19.3M; G&A increased to $34.3M from $4.7M, including $20.8M of non-cash former CEO award-modification expense.

• 9M operating expenses were $134.5M vs. $72.3M and net loss was $123.0M vs. $64.9M; interest and other income rose to $11.5M from $7.4M.

• 9M net cash used in operations was $77.7M vs. $61.6M; financing provided $189.4M and cash and cash equivalents increased $86.6M.

Outlook and guidance

• The current operating plan estimated existing cash, cash equivalents and marketable securities would fund projected operating expenses and capital needs into 2029; the estimate depends on assumptions that may prove incorrect.

• Expenses and operating losses were expected to rise substantially as canvuparatide, MBX 4291, MBX 5765 and MBX 6180 advance; no product revenue was expected before successful development and regulatory approval.

• First-cohort results from the 12-week MBX 4291 MAD Phase 1 study were expected in Q4 2026; MBX 6180 preclinical data were expected at ObesityWeek 2026.